Where does Ligand Pharmaceuticals's cash flow data come from?

Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$153.56M+216%	$124.45M+3,187%	$48.58M+7.4%	-$75.86M-280%	-$132.62M-238%
Depreciation and amortization	$33.22M-5.7%	$33.78M-4.2%	$34.19M-3.8%	$34.91M-0.7%	$35.24M-1.5%
Stock-based compensation	$49.61M+19.3%	$46.85M+14.0%	$40.1M+2.1%	$40.53M+30.7%	$41.59M+53.2%
Deferred income taxes	-$18M-141%	-$22.68M-244%	$579K+132%	$23.85M+302%	$44.19M+297%
Amortization of debt issuance costs	$1.94M+261%	$1.27M+162%	$880K+123%	$567K+117%	$538K+135%
Change in accounts receivable	$14.75M—	$21.74M—	$25.32M—	——	——
Change in inventories	-$1.35M+79.2%	-$4.99M+48.1%	-$4.78M+32.2%	-$3.12M+30.8%	-$6.49M-159%
Change in accounts payable	$10.75M-18.2%	$5.88M-57.7%	$9.82M—	$10.96M—	$13.14M—
Other working capital changes	——	——	$6.54M+642%	$6.34M+571%	$6.08M—
Change in deferred revenue	——	——	——	-$946K-83.3%	-$1.06M-4,513%
Change in income taxes payable/receivable	——	——	-$6.54M—	$3.42M—	$4.89M—
Net gains (losses) on investments	-$529K-556%	$181K+302%	$49K-62.3%	$92K+188%	$116K—
Net cash from operating activities	$123.5M+134%	$49.36M-49.1%	$31.92M-58.4%	$55.36M+15.9%	$52.87M+53.5%
Capital expenditures	$466K-75.9%	$452K-75.2%	$1.16M-24.3%	$1.74M+22.5%	$1.93M+59.2%
Purchases of investments	——	——	——	——	——
Proceeds from maturities/sales of investments	$122.47M-40.8%	$159.58M-30.4%	$78.4M-67.6%	$168.87M+6.3%	$206.86M+25.0%
Net cash from investing activities	-$476.56M-253%	-$377.32M-163%	-$397.84M-245%	-$90.9M-2.9%	-$135M-419%
Proceeds from issuance of common stock	$3.43M-86.8%	$0-100%	$3.11M-90.9%	$24.75M+101%	$26.06M+119%
Payments for finance leases	$27K0.0%	$27K+8.0%	$26K+8.3%	$30K+7.1%	$27K-27.0%
Taxes paid for net share settlement	$22.44M+105%	$9.6M+86.9%	$11.19M+224%	$11.1M+223%	$10.95M+216%
Payment of debt issuance costs	$15.51M+3,301%	$15.53M+3,545%	$15.03M+1,096%	$401K-61.7%	$456K-53.9%
Net cash from financing activities	$418.84M+422%	$428.22M+341%	$440.28M—	$85.72M—	$80.21M—
Effect of exchange rate changes on cash	——	——	——	$2.18M—	-$113K—
Net increase (decrease) in cash	$67.11M+3,289%	$102.62M+108%	$75.76M—	$49.53M—	-$2.1M—
Net cash from discontinued operations	——	——	——	——	——
Interest paid	$321K+6.6%	$321K+22.1%	$300K—	$352K—	$301K—
Income taxes paid	$8.3M-57.4%	$7.8M-59.4%	$7.04M-73.1%	$17.99M+23.7%	$19.49M—
Accretion (Amortization) of Discounts and Premiums, Investments	$5.62M+179%	$4.96M+273%	$3.55M+221%	$2.35M+88.5%	$2.01M+68.7%
Non-cash interest expense	$1.94M+261%	$1.27M+162%	$880K+123%	$567K+117%	$538K+135%
CECL adjustment to financial royalty assets	-$597K—	-$948K—	-$1.6M—	——	——
Lease amortization expense	$1.85M-16.6%	$1.94M-8.7%	$2.03M-1.3%	$2.13M+16.9%	$2.22M+25.7%
Gain (Loss) on Disposition of Other Assets	——	$53.07M—	$39.8M—	$26.54M—	$13.27M—
Gain (Loss) on Short-term Investments	——	——	——	——	——
Increase (Decrease) in Deferred Income Taxes	-$18M-141%	-$22.68M-244%	$579K+132%	$23.85M+302%	$44.19M+297%
Increase (Decrease) in Income Taxes Receivable	——	——	-$6.54M-180%	$3.42M-63.2%	$4.89M+530%
Non Cash Change In Estimated Fair Value Of Contingent Value Rights	——	——	——	——	——
Non-cash Income From Financial Royalty Assets	$3.36M-43.3%	$8.62M+57.7%	$2.03M-56.7%	$6.36M+9,110%	$5.93M+1,076%
Gain (loss) on mark-to-market of Escrowed Shares	$359K+102%	$1.02M+105%	-$5.49M+61.9%	-$21.95M-1,228%	-$20.38M-4,670%
Increase Decrease In Intangible Assets Current	——	$0—	$0-100%	$0-100%	$0-100%
Payments For Derivative Instrument Investing Activities	$6.17M-19.0%	$13.79M—	$8.68M—	$7.62M—	$7.62M—
Payments To Acquire Financial Royalty Assets	$9.04M-47.4%	$10.86M-39.0%	$10.21M-85.0%	$15.47M-71.6%	$17.2M-67.4%
Payments to Acquire Other Investments	——	$3.85M+53.9%	$3.51M+87.2%	$3.17M+154%	$2.84M+354%
Payments to Acquire Short-Term Investments	$889.52M+327%	$726.71M+221%	$607.61M+297%	$247.03M+76.6%	$208.12M+26.5%
Proceeds From Derivative Instrument Investing Activities	——	——	——	——	$5.34M+200%
Proceeds from financial royalty assets	$14.09M+63.2%	$10.26M+38.1%	$11.3M+128%	$8.4M+90.4%	$8.64M+287%
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments	$304.69M+498%	$217.7M+557%	$141.89M+303%	$92.74M+91.8%	$50.95M-1.0%
Proceeds From Sale Of Short Term Investments	$122.47M-40.8%	$159.58M-30.4%	$78.4M-67.6%	$168.87M+6.3%	$206.86M+25.0%
Finance Lease, Principal Payments	$27K0.0%	$27K+8.0%	$26K+8.3%	$30K+7.1%	$27K-27.0%
Payments Of Debt Issuance Costs	$15.51M+3,301%	$15.53M+3,545%	$15.03M+1,096%	$401K-61.7%	$456K-53.9%
Accrued purchases of financial royalty assets	——	$0—	$0-100%	$0-100%	$0-100%
Accrued royalty from financial royalty assets	——	$0—	$0-100%	$0-100%	$0-100%
Increase (decrease) in cash, cash equivalents, and restricted cash	——	——	——	——	——
Less: Net increase (decrease) in cash classified within assets held for sale	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	$2.35M+35.1%	$2.6M—
Unrealized Gain (Loss) on Investments	-$529K-556%	$181K+302%	$49K-62.3%	$92K+188%	$116K—
Free cash flow	$123.03M+142%	$48.91M-48.6%	$30.76M-59.0%	$53.62M+15.7%	$50.94M+52.4%
Free cash flow	$123.03M+142%	$48.91M-48.6%	$30.76M-59.0%	$53.62M+15.7%	$50.94M+52.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Ligand Pharmaceuticals's cash flow data come from?: Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.